Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus platinum-etoposide for extra-pulmonary small cell carcinoma
ACTRN12621001225808Phase 2Completed
- Sponsor
- The University of Sydney
- Start
- May 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, cisplatin, carboplatin, etoposide and etoposide phosphate in small cell carcinoma (SCC), sponsored by The University of Sydney. Primary endpoint: Progression-free survival at 12 months. Started May 2022; status: completed.
02
Drugs
durvalumabcisplatincarboplatinetoposideetoposide phosphate
03
Conditions
small cell carcinoma (SCC)
Beyond the preview
Go deeper on ACTRN12621001225808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001225808.